IL154144A0 - Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract - Google Patents

Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract

Info

Publication number
IL154144A0
IL154144A0 IL15414401A IL15414401A IL154144A0 IL 154144 A0 IL154144 A0 IL 154144A0 IL 15414401 A IL15414401 A IL 15414401A IL 15414401 A IL15414401 A IL 15414401A IL 154144 A0 IL154144 A0 IL 154144A0
Authority
IL
Israel
Prior art keywords
common cold
respiratory tract
allergic rhinitis
treating symptoms
infections relating
Prior art date
Application number
IL15414401A
Other languages
English (en)
Original Assignee
Immupharm Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immupharm Aps filed Critical Immupharm Aps
Publication of IL154144A0 publication Critical patent/IL154144A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15414401A 2000-07-28 2001-07-23 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IL154144A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200001152 2000-07-28
DKPA200001316 2000-09-04
DKPA200001935 2000-12-23
DKPA200100007 2001-01-03
DKPA200100827 2001-05-22
PCT/DK2001/000515 WO2002009699A2 (en) 2000-07-28 2001-07-23 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract

Publications (1)

Publication Number Publication Date
IL154144A0 true IL154144A0 (en) 2003-07-31

Family

ID=27512989

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15414401A IL154144A0 (en) 2000-07-28 2001-07-23 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
IL154144A IL154144A (en) 2000-07-28 2003-01-27 Use of an effective medical dose of flavonoid for the preparation of a drug to treat the symptoms of influenza, allergic rhinitis and respiratory infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154144A IL154144A (en) 2000-07-28 2003-01-27 Use of an effective medical dose of flavonoid for the preparation of a drug to treat the symptoms of influenza, allergic rhinitis and respiratory infections

Country Status (19)

Country Link
US (2) US7166640B2 (enExample)
EP (1) EP1307189B1 (enExample)
JP (1) JP2004505046A (enExample)
KR (1) KR100824075B1 (enExample)
CN (1) CN100411617C (enExample)
AT (1) ATE325612T1 (enExample)
AU (2) AU2001279587B2 (enExample)
BR (1) BR0112818A (enExample)
CA (1) CA2416899C (enExample)
DE (1) DE60119534T2 (enExample)
DK (1) DK1307189T3 (enExample)
EA (1) EA008612B1 (enExample)
ES (1) ES2263643T3 (enExample)
IL (2) IL154144A0 (enExample)
MX (1) MXPA03000848A (enExample)
NO (1) NO20030337L (enExample)
NZ (1) NZ524121A (enExample)
PL (1) PL203216B1 (enExample)
WO (1) WO2002009699A2 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10122714A1 (de) * 2001-05-10 2002-11-21 Brench Ag Verwendung von Rutinen und Aescinen zur Behandlung okulärer Durchblutungsstörungen
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
EP2108370A1 (en) 2002-04-30 2009-10-14 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
US8945518B2 (en) 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
FR2845597B1 (fr) * 2002-10-11 2005-03-11 Innothera Lab Sa Formulation orale seche contenant de la diosmine sous forme pharmaceutique de comprime a croquer
ATE381323T1 (de) * 2002-10-24 2008-01-15 Immupharm As Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol
DE602004022635D1 (de) * 2003-01-21 2009-10-01 Wei-Wei Su Verwendung von naringenin, naringin und salzen daraus als schleimlöser bei der behandlung von husten sowie zusammensetzungen daraus
CN1798568B (zh) 2003-04-04 2011-05-11 尤尼根制药公司 用于哺乳动物皮肤护理的双重环氧合酶(cox)以及脂氧合酶(lox)抑制剂的组合物
CN1816538B (zh) 2003-07-22 2011-05-25 协和发酵生化株式会社 病毒感染症的预防或者治疗用组合物
DE10361444A1 (de) * 2003-12-23 2005-07-21 Axaron Bioscience Ag Verfahren zur in vitro Differenzierung neuronaler Stammzellen oder von neuronalen Stammzellen abgeleiteter Zellen
KR100832667B1 (ko) 2004-02-05 2008-05-27 액세스 비지니스 그룹 인터내셔날 엘엘씨 항알레르기 조성물 및 관련 방법
WO2005104722A2 (en) 2004-04-28 2005-11-10 Hutchison Medipharma Enterprises Limited Crude extracts from andrographis paniculata
CA2575932A1 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
TW200630102A (en) * 2004-10-19 2006-09-01 Unigen Pharmaceuticals Inc Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
WO2006082435A1 (en) * 2005-02-04 2006-08-10 Viranative Ab Method and use of interferon compositions for the treatment of avian influenza
CN101137639B (zh) * 2005-03-11 2012-05-23 霍华德弗洛里生理医学实验研究所 类黄酮化合物及其用途
US7910620B2 (en) * 2005-04-22 2011-03-22 Broadhurst Iii Jack J Uses of neuraminidase inhibitors in infectious diseases
EP2705845B1 (en) * 2006-01-27 2016-10-05 Yale University Combination of zinc salt and anti-h pilori agent as fast acting inhibitor of gastric acid secretion
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
CN101405015B (zh) * 2006-03-24 2015-04-01 乔治斯·潘达利斯 用于预防和治疗普通感冒病的组合物
WO2007125731A1 (ja) * 2006-04-28 2007-11-08 Menicon Co., Ltd. ソフトコンタクトレンズ用溶液及びそれを用いて得られる薬剤徐放性ソフトコンタクトレンズ並びにその製造方法
KR100792626B1 (ko) * 2006-05-30 2008-01-09 프로테온 주식회사 카테킨 유도체 화합물을 유효성분으로 하는 독감 바이러스감염성 질환 예방 및 치료제
KR100770746B1 (ko) * 2006-06-15 2007-10-30 제주대학교 산학협력단 항염활성을 갖는 감귤 유래 노빌레틴과 그 분리.정제방법
WO2008016593A2 (en) 2006-07-31 2008-02-07 Trustees Of Columbia University In The City Of New York Bioactive depside and anthocyanin compounds, compositions, and methods of use
RU2315593C1 (ru) * 2006-08-02 2008-01-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Липосомальная композиция антиоксидантов для ингаляций при заболеваниях легких и верхних дыхательных путей
US8465782B2 (en) * 2006-09-21 2013-06-18 Immune Guard, LLC Methods and materials for reducing risk of cold and/or flu
AU2007354255A1 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
PT2101792E (pt) 2006-12-05 2010-06-25 Marinomed Biotechnologie Gmbh Utilização de carragenina para tratamento de infecções por rinovírus
WO2008106979A2 (en) * 2007-03-02 2008-09-12 Immupharm A/S Pharmaceutical compositions comprising flavonoids and xylitol
KR100853442B1 (ko) * 2007-08-21 2008-08-21 프로테온 주식회사 카테킨 유도체 화합물을 유효성분으로 하는 독감 바이러스감염성 질환 예방용 건강식품
US20090117209A1 (en) * 2007-11-02 2009-05-07 Hutchison Medipharma Enterprises Limited Andrographis paniculata extract
KR100999872B1 (ko) * 2008-06-12 2010-12-09 한국생명공학연구원 홍경천 추출물, 홍경천 분획물, 이로부터 분리한플라보노이드계 화합물, 이의 유도체 화합물 또는 이의약학적으로 허용 가능한 염을 유효성분으로 함유하는바이러스 질환의 예방 및 치료용 약학적 조성물
WO2009151173A1 (en) * 2008-06-12 2009-12-17 Korea Research Institute Of Bioscience And Biotechnology Pharmaceutical compositions for prevention and treatment of viral diseases containing rhodiola extracts, fractions, the isolated flavonoid compounds therefrom, derivatives compounds thereof or the pharmaceutically acceptable salts as an active ingredient
US20100009012A1 (en) * 2008-07-11 2010-01-14 Zukkoor N David Chewable pharyngeal inflammation symptom relief composition
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US20150005325A1 (en) * 2009-06-16 2015-01-01 Biocopea Limited Drug Combinations and Uses in Treating a Coughing Condition
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
JP5617097B2 (ja) * 2010-05-13 2014-11-05 敏彦 四宮 亜鉛錯体とプロスタグランジン等からなる外用剤
EP2582373A4 (en) 2010-06-16 2013-10-30 Bruce Chandler May USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COLLECTIONS AND INFLAMMATION
CN101891783B (zh) * 2010-06-23 2013-04-03 四川大学 黄酮-金属络合微球及其制备方法与应用
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
CN102048726A (zh) * 2011-01-10 2011-05-11 华东理工大学 川陈皮素的应用
CN103648491B (zh) * 2011-04-08 2017-07-14 法国国家健康医学研究院 用于抑制流感病毒复制的方法和药物组合物
CN102343083A (zh) * 2011-10-17 2012-02-08 中国科学院成都生物研究所 一种抗病毒的组合药物
US20210260144A1 (en) * 2012-01-27 2021-08-26 The Trustees Of The University Of Pennsylvania Quinine and its use to generate innate immune response
AU2013287630B2 (en) 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CA2901421A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of autoimmune disorders
ES2660494T3 (es) 2013-03-13 2018-03-22 14779507 Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
EP3037132B1 (en) * 2014-12-23 2018-10-31 Farma-Derma S.R.L. Zinc salt and polyphenol composition
DE102015115876A1 (de) * 2015-09-21 2017-03-23 Eberhard Karls Universität Tübingen Medizinische Fakultät Substanz zur Prophylaxe und Behandlung von Infektionen durch Influenzaviren
CN105461676B (zh) * 2015-11-20 2017-12-12 上海秉丰生物科技有限公司 一种伪麻黄碱类衍生物及其制备方法与应用
MX2018010198A (es) * 2016-02-25 2019-06-12 Applied Biological Laboratories Inc Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire.
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
CN106265630A (zh) * 2016-10-13 2017-01-04 吉林大学 穗花杉双黄酮在研发治疗肺炎药物中的应用
FR3057773B1 (fr) * 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
CA3041644C (en) * 2016-10-24 2020-03-10 Colgate-Palmolive Company Oral care compositions and methods of use
CN106667997A (zh) * 2017-02-27 2017-05-17 吉林大学 表没食子儿茶素没食子酸酯抑制肺炎链球菌致病力及应用
CN106667996B (zh) * 2017-02-27 2019-04-09 吉林大学 桑色素在制备抗猪链球菌病药物中的应用
CN108484751B (zh) * 2018-04-19 2020-06-23 西南大学 川陈皮素抗原及其制备方法与应用
CN108704074A (zh) * 2018-06-27 2018-10-26 陶燃 一种治疗慢性鼻炎的药物组合物及其应用
US11304968B2 (en) 2018-11-16 2022-04-19 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide
US10639294B2 (en) 2018-10-02 2020-05-05 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a hydroxyethylquercetin glucuronide metabolite
EP3920886A1 (en) * 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Taz activators and wnt agonists for treating ear disorders
US10993958B1 (en) * 2020-03-16 2021-05-04 William B. Coe Aldehyde functional monoterpenoids for the treatment of coronavirus infection
WO2021188575A1 (en) * 2020-03-16 2021-09-23 Coe William B Dietary supplement comprising aldehyde functional monoterpenoids
WO2021207176A1 (en) * 2020-04-06 2021-10-14 Humanetics Corporation Genistein treatment of inflammatory pulmonary injury
JP2023523035A (ja) * 2020-04-21 2023-06-01 コーエン ノーム キニーネ及び先天性免疫応答を生じさせるためのその使用
WO2021240481A2 (en) * 2020-05-29 2021-12-02 Vedicinals India Private Limited A composition for management of covid-19 and associated disorders
US20230301959A1 (en) * 2020-07-01 2023-09-28 Deanna J. Nelson Combinations of carnosine and zinc for the treatment and prevention of viral infections
CN111643626A (zh) * 2020-07-21 2020-09-11 马良成 一种用于感冒、鼻炎、晕车的外用粉剂
JP2023536841A (ja) * 2020-07-27 2023-08-30 シーエイエス プロパティーズ リミテッド ライアビリティ カンパニー Ｃｏｖｉｄ－１９及び関連する病態の治療及び予防のためのノビレチン組成物ならびに方法
CN111920801A (zh) * 2020-09-18 2020-11-13 郑州大学第一附属医院 表没食子儿茶素没食子酸酯在制备治疗和/或预防埃克病毒感染所致疾病的药物中的用途
WO2022059012A1 (en) * 2020-09-21 2022-03-24 Ramot At Tel-Aviv University Ltd. Combination compositions having anti-viral activities and uses thereof
CN114432288A (zh) * 2020-11-02 2022-05-06 苏州凯祥生物科技有限公司 黄酮类化合物在制备预防或治疗急性肺损伤或急性呼吸窘迫综合征的药物中用途
WO2022203547A1 (ru) * 2021-03-24 2022-09-29 Общество с ограниченной ответственностью "Научная Компания "Фламена" Применение фосфолипидной эмульсии для лечения гестозов первого триместра
RU2757360C1 (ru) * 2021-03-24 2021-10-14 Общество с ограниченной ответственностью "Научная Компания "Фламена" Применение фосфолипидной эмульсии, содержащей эффективное количество дигидрокверцетина, лецитин и глицин для лечения воспалительных заболеваний органов дыхания
CN113384572A (zh) * 2021-06-11 2021-09-14 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 羟基芫花素在制备抗冠状病毒药物中的应用
US20220401403A1 (en) * 2021-06-14 2022-12-22 Global Biolife Inc. Method and composition for preventing and treating viral infections
US20230119141A1 (en) * 2021-10-19 2023-04-20 Phyto Tech Corp. Uses of taxifolin for respiratory health
CN113896702A (zh) * 2021-10-29 2022-01-07 晨光生物科技集团股份有限公司 一种槲皮万寿菊素-3-衍生物及用途
US11975009B2 (en) * 2022-05-02 2024-05-07 Znable Llc Use of zinc porphyrin as an antimicrobial

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH423808A (fr) * 1964-03-26 1966-11-15 Zyma Sa Procédé pour la préparation d'éthers O-B-hydroxyéthylés de la rutine
FR5072M (enExample) 1965-10-25 1967-05-16
US4956385A (en) * 1981-07-31 1990-09-11 Eby Iii George A Method for reducing the duration of the common cold
ATE22533T1 (de) * 1982-04-29 1986-10-15 Efamol Ltd Pharmazeutische zusammensetzung.
EP0172893A4 (en) * 1984-03-01 1987-05-13 John Royle Casley-Smith TREATMENT OF OEDEMAS WITH A HIGH PROTEIN CONTENT IN ANIMALS.
EP0204987B1 (de) * 1985-05-15 1991-11-21 Roshdy Dr. Ismail Vitamin E-haltiges Mittel zur Verbesserung der Eigenschaften des Blutes
DE3603227A1 (de) * 1986-02-03 1987-08-20 Andreas Dipl Chem Ing D Vincze Pharmazeutische zubereitung, die als aktive substanz eine mischung von (+) catechin und ascorbolysinat enthaelt
WO1988003805A1 (en) * 1986-11-19 1988-06-02 Chemex Pharmaceuticals, Inc. Pharmacologically active compounds and mixtures thereof, organic compositions and metal salts
JPH01501790A (ja) * 1986-11-19 1989-06-22 ケメックス　ファーマシューティカルズ，インコーポレイティド リポキシゲナーゼ阻害剤
EP0396251A3 (en) 1989-03-31 1992-07-08 National University Of Singapore Use of fatty acids for the treatment of diseases associated with cytokines
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
EP0505374B1 (en) * 1990-10-16 1997-04-23 Mayor Pharmaceuticals Laboratories,Inc. Vitamin-mineral treatment methods and compositions
JPH04368331A (ja) 1991-06-17 1992-12-21 Nippon Oil & Fats Co Ltd 抗ｒｓウイルス剤
JPH08239319A (ja) * 1995-03-01 1996-09-17 Sanji Kumai 風邪予防トローチ
US5888527A (en) * 1995-05-11 1999-03-30 Matsushita Seiko Co., Ltd. Gargling cup, antiviral mask, antiviral filter, antifungal, antibacterial, and antiviral filter air cleaner and air-cleaner humidifier
JPH0956333A (ja) 1995-08-21 1997-03-04 Kozaburo Shiba 機能性梅チョコレート
US5649877A (en) * 1995-08-21 1997-07-22 Sram Corporation Linear derailleur
ATE548351T1 (de) * 1996-01-29 2012-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Dihydropyridin-pyridin-, benzopyranon- und triazolochinazolin-derivate, deren herstellung und verwendung als adenosinrezeptor-antagonisten
JPH09227373A (ja) 1996-02-21 1997-09-02 Teijin Ltd 抗インフルエンザウイルス剤
JP3585328B2 (ja) 1996-10-07 2004-11-04 株式会社エクセディ 粘性ダンパー機構
JPH10114653A (ja) * 1996-10-11 1998-05-06 Taishi Shokuhin Kogyo Kk 骨形成促進および骨塩量減少防止用組成物
AU5910998A (en) * 1997-01-13 1998-08-03 Emory University Compounds and their combinations for the treatment of influenza infection
US5840278A (en) * 1997-02-20 1998-11-24 Coleman; Thomas Nasal spray having a mineral vitamin component, a mineral component and aloe vera
JP3202938B2 (ja) * 1997-03-18 2001-08-27 三井農林株式会社 チューインガム及びその製造法
US5834000A (en) 1997-04-11 1998-11-10 Yng-Wong; Quing Non Antiviral and antimicrobial herbal complex
WO1998047534A1 (de) * 1997-04-18 1998-10-29 Klinge Pharma Gmbh Stabilisiertes arzneimittel enthaltend cysteinylderivate
JP4676040B2 (ja) * 1997-07-31 2011-04-27 株式会社林原生物化学研究所 組成物
US6224872B1 (en) * 1997-07-31 2001-05-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition
WO1999007381A1 (en) * 1997-08-11 1999-02-18 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
EP1037534A4 (en) * 1997-09-29 2005-04-06 China Innovation Ct For Life S FAGOPYRUM CYMOSUM (TREV.) MEISN COMPOSITION, PROCESS FOR PREPARING AND ANALYZING THE SAME AND USES THEREOF
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
JP2000327573A (ja) * 1999-05-18 2000-11-28 Taisho Pharmaceut Co Ltd 粘膜適用組成物
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
AU6174900A (en) * 1999-07-08 2001-01-30 Patrick T. Prendergast Use of flavones, coumarins and related compounds to treat infections
DE19949575A1 (de) * 1999-10-14 2001-04-19 Michael Hermann Hinz Neuartige Wirkstoffkombination von biologisch hochwirksamen Fluoriden u. Flavonoiden zur Therapie und Prphylaxe von Zahnerkrankungen
FI20000004A0 (fi) * 2000-01-03 2000-01-03 Slk Foundation Flavonoidilääke...
FR2822380B1 (fr) * 2001-03-23 2004-01-30 Oreal Utilisation d'un melange comprenant mn (ii) et/ou zn (ii) avec un hydrogenocarbonate et au moins un orthodiphenol, en tant qu'agent diminuant l'adhesion des micro-organismes

Also Published As

Publication number Publication date
ATE325612T1 (de) 2006-06-15
CA2416899A1 (en) 2002-02-07
PL203216B1 (pl) 2009-09-30
JP2004505046A (ja) 2004-02-19
PL360140A1 (en) 2004-09-06
WO2002009699A2 (en) 2002-02-07
US7166640B2 (en) 2007-01-23
US8003688B2 (en) 2011-08-23
NO20030337L (no) 2003-03-21
CA2416899C (en) 2010-10-12
EP1307189A2 (en) 2003-05-07
DE60119534D1 (de) 2006-06-14
AU2001279587B2 (en) 2006-08-17
KR20030036648A (ko) 2003-05-09
NZ524121A (en) 2005-09-30
US20050245467A1 (en) 2005-11-03
KR100824075B1 (ko) 2008-04-22
CN100411617C (zh) 2008-08-20
EA200300190A1 (ru) 2003-08-28
AU7958701A (en) 2002-02-13
DK1307189T3 (da) 2006-09-18
EA008612B1 (ru) 2007-06-29
BR0112818A (pt) 2004-10-19
CN1466454A (zh) 2004-01-07
WO2002009699A3 (en) 2003-01-03
US20040053858A1 (en) 2004-03-18
HK1057330A1 (en) 2004-04-02
DE60119534T2 (de) 2007-05-10
EP1307189B1 (en) 2006-05-10
IL154144A (en) 2007-07-24
ES2263643T3 (es) 2006-12-16
NO20030337D0 (no) 2003-01-22
MXPA03000848A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
AU7958701A (en) Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
WO2004019884A3 (en) Agents and methods for enhancing bone formation
WO2003099207A3 (en) Oral lactoferrin in the treatment of respiratory disorders
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
WO2003000241A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika; corticosteroiden und betamimetika zur behandlung von entzündlichen und/oder obstruktiven atemwegserkrankungen
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
MXPA04005865A (es) Suministro de aminoglucosidos a los pulmones.
ATE318601T1 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
MY122838A (en) Treating allergic and inflammatory conditions
SE0401631L (sv) Ny sammansättning
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
MY130725A (en) Composition and method for treating allergic diseases
WO2003092701A3 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
WO2002067938A3 (en) Treating or reducing the risk of cardiovascular disease
ATE526954T1 (de) Atomoxetin zur behandlung von allergischer rhinitis und asthma
UA32651C2 (uk) Спосіб напіввідкритої лапаростомії
UA37488A (uk) Спосіб лікування хронічного кон'юнктивіту

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed